Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis

BACKGROUND: Therapeutic options targeting inflammation in multiple sclerosis (MS) have evolved rapidly for relapsing–remitting MS, whereas few therapies are available for progressive forms of MS, in particular secondary progressive MS (SPMS). The approval of siponimod for SPMS has allowed for optimi...

Descripción completa

Detalles Bibliográficos
Autores principales: Regner-Nelke, Liesa, Pawlitzki, Marc, Willison, Alice, Rolfes, Leoni, Oezalp, Sinem-Hilal, Nelke, Christopher, Kölsche, Tristan, Korsen, Melanie, Grothe, Matthias, Groppa, Sergiu, Luessi, Felix, Engel, Sinah, Nelles, Gereon, Bonmann, Eckhard, Roick, Holger, Friedrich, Anke, Knorn, Philipp, Landefeld, Harald, Biro, Zoltan, Ernst, Michael, Bayas, Antonios, Menacher, Martina, Akgün, Katja, Kleinschnitz, Christoph, Ruck, Tobias, Ziemssen, Tjalf, Pul, Refik, Meuth, Sven G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639325/
https://www.ncbi.nlm.nih.gov/pubmed/36336685
http://dx.doi.org/10.1186/s42466-022-00219-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639325/
https://www.ncbi.nlm.nih.gov/pubmed/36336685
http://dx.doi.org/10.1186/s42466-022-00219-3

Ejemplares similares